Clinical Trial Update: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating tucatinib plus ado-trastuzumab emtansine (T-DM1) versus placebo plus T-DM1 in advanced or metastatic HER2-positive breast cancer. Resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)
• Tukysa (tucatinib)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-07-30